Adelaide drug company Bionomics says it’s cashed up and has a...

Adelaide drug company Bionomics says it’s cashed up and has a strong development pipeline
http://www.adelaidenow.com.au/busin...e/news-story/13c75a52e9f82c1d4a800286cc27a261
BNC210 trial: "... data is anticipated by 30 September 2016."

http://finfeed.com/biotech/pfizer-deal-brings-cancer-companies-spotlight/20160824/
"In framing medium-term earnings projections Jain is assuming that BNC210 is licensed in the second half of fiscal 2017 for a deal worth US$345 million and double-digit royalties on sales.
Based on these projections net profit would be an estimated $46.1 million representing earnings per share of 9.5 cents. Should this scenario play out, and the earnings forecasts be achieved BNO is trading on a PE multiple of less than three relative to yesterday’s closing price."

Reminder that Bionomics has agreement to earn up to $687M with Merc + royalties on sales made up from:
- Pain up to $172M
- Altzimers $500M+
Dr D is expecting one or two payments from Merc before the end of 2016.

Obviously I am bullish, and picked up 40,000 shares today @ 24.5c